

# Japan

Population 2017

127 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	2.8 (2.7–2.9)	2.2 (2.1–2.3)
Mortality (HIV+TB only)	0.013 (<0.01–0.019)	0.01 (0.01–0.01)
Incidence (includes HIV+TB)	19 (17–22)	15 (13–17)
Incidence (HIV+TB only)	0.085 (0.07–0.1)	0.07 (0.05–0.08)
Incidence (MDR/RR-TB)**	0.57 (0.24–1.1)	0.45 (0.18–0.83)

## Estimated TB incidence by age and sex (thousands)\*, 2017

	0-14 years	> 14 years	Total
Females	0.79 (0.77–0.81)	6.9 (6.3–7.5)	7.7 (7–8.4)
Males	1 (0.97–1)	11 (9.4–12)	12 (10–13)
Total	1.8 (1.7–1.9)	18 (15–20)	19 (17–22)

## TB case notifications, 2017

Total cases notified	16 789
Total new and relapse	16 789
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	9%
- % pulmonary	77%
- % bacteriologically confirmed among pulmonary	86%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.15 (0.12–0.17)

## TB/HIV care in new and relapse TB patients, 2017

	Number	(%)
Patients with known HIV-status who are HIV-positive	34	2%
- on antiretroviral therapy		

Drug-resistant TB care, 2017	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			360 (140–590)
Estimated % of TB cases with MDR/RR-TB	2.3% (0.86–4.4)	12% (7.2–19)	
% notified tested for rifampicin resistance	52%	46%	8 856
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: 86, XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2016	70%	17 539
Previously treated cases, excluding relapse, registered in 2016		
HIV-positive TB cases registered in 2016	57%	44
MDR/RR-TB cases started on second-line treatment in 2015		
XDR-TB cases started on second-line treatment in 2015		

## TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	55% (41–86)

## TB financing, 2018

National TB budget (US\$ millions)	43
------------------------------------	----

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2017



## Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB